Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid

Netherlands Journal of Medicine

Volumn 63, Issue 5, 2005, Pages 184-186

  Huvers, F ^a   Slappendel, R ^a   Benraad, B ^a   van Hellemondt, G ^a   van Kraaij, M ^b  

^a Sint Maartenskliniek ^*  (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Activated; Bleeding; Clearance; Factor VII; Female; Fibrinolysis; Fondaparinux; Haemorrhagic; Orthopaedic; Pentasaccharide; Postoperative; Recombinant; Renal; Shock; Surgery; Tranexamic acid

Indexed keywords

CITRATE CALCIUM; FIBRIN; FONDAPARINUX; HEMOGLOBIN; INDAPAMIDE; OMEPRAZOLE; PARACETAMOL; PROTHROMBIN; RALOXIFENE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; THROMBOPLASTIN; TRANEXAMIC ACID;

AGED; ARTICLE; BLOOD CLOTTING; CASE REPORT; DEEP VEIN THROMBOSIS; DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; FIBRINOLYSIS; HEMORRHAGIC SHOCK; HEMOSTASIS; HIP PROSTHESIS; HUMAN; HYPERTENSION; KIDNEY CLEARANCE; ORTHOPEDIC SURGERY; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; POSTOPERATIVE HEMORRHAGE; PROTHROMBIN TIME; REOPERATION; SINGLE DRUG DOSE; SUBTOTAL THYROIDECTOMY; TOTAL HIP PROSTHESIS; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; ARTHROPLASTY, REPLACEMENT, HIP; DRUG THERAPY, COMBINATION; FACTOR VII; FEMALE; HUMANS; INTRAOPERATIVE PERIOD; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; POLYSACCHARIDES; POSTOPERATIVE HEMORRHAGE; PROTHROMBIN TIME; RECOMBINANT PROTEINS; TRANEXAMIC ACID; VENOUS THROMBOSIS;

EID: 20444397756     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119(l):S132-75.
2. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162(16):1833-40.
3. Slappendel R, Dirksen R, Weber EW, van der Schaaf DB An algorithm to reduce allogenic red blood cell transfusions for major orthopedic surgery. Acta Orthop Scand 2003;74(5):569-75.
4. Bijsterveld N R, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002;l06(20):2550-4.
5. Gerotziafas GT, Depasse F, Chakroun T, Samama MM, Elalamy I. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost 2004;91(3):531-7.
6. Lisman T, Bijsterveld NR, Adelmeijer J, et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 2003;1(11):2368-73.
7. Samama MM, Gerotziafas GT. Evaluation ofthe pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 2003;109(1):1-11.
8. Kamphuisen PW, Levi M, van Kraaij MG, Kaasjager HA, Frolke JP. Diagnostic and pharmaco-therapeutic options in acute severe blood loss. Ned Tijdschr Geneeskd 2004;148(39):1907-11.